Omniscient Secures Series D Funding

Omniscience, a leader in AI-driven brain analysis technology, has successfully secured $27.2 million (AU$41.1 million) in an oversubscribed Series D funding round. The funding was co-led by VSR Ventures Private Limited and the Japan — National Reconstruction Fund Corporation, with continued support from long-term investors Will Vicars and Gina Rinehart. This capital will be used to accelerate the commercial expansion of Omniscience's FDA-cleared Quicktome platform and develop new clinical applications, extending its reach into high-growth markets such as brain computer interface, stroke, and movement disorders. The company's connectomics technology uses AI to decode individual brain wiring, generating patient-specific maps that visualize functional regions and neural pathways. This development follows a major reimbursement breakthrough with CPT code 1039T, establishing a billing pathway for connectomic analysis in the United States healthcare system.